Characteristic analysis of retinopathy associated with high doses of interferon α-2b therapy in pati

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户：VIPYJS

【摘要】

：

　　Objective: To observe and analyze the retinopathy associated with high doses of interferon α-2b therapy in patients with melanomas of the skin.Method: Eigh

【作者】

：

ShijieLan[1]ZhihuaCui[2]ZhigangLiu[3]JianliCui[3]LinglingLiang[2]DiWu[1]

【机构】

：

Cancer Center, the First Hospital of Jilin University

【出处】

：

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会

【发表日期】

：

2015年期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　Objective: To observe and analyze the retinopathy associated with high doses of interferon α-2b therapy in patients with melanomas of the skin.Method: Eighteen patients with melanomas of the skin whose tumors have been resected completely were collected.

其他文献

Study design: A retrospective study to evaluate the diagnosis of EGFR mutations detected by the coba

　　Objective: Activating mutations in the gene encoding EGFR occur primarily in non-small cell lung cancer (NSCLC) and result in constitutive activation of the

会议

肿瘤无病理诊断及病理与临床诊断不一致的成因和对治疗的影响--基于临床医生的评价

　　目的：研究临床实践中肿瘤病人无病理诊断的发生率及成因，病理诊断与临床诊断不一致的比例及其影响因素，以及由此而对临床治疗产生的影响。方法：收集安徽医科大学第二附属医院

会议

肿瘤中心病理诊断临床诊断成因临床治疗安徽医科大学住院患者肿瘤病人

消癌平注射液改善非小细胞肺癌细胞对gefitinib和erlotinib双重耐药的作用及机理

　　目的：通过吉非替尼(gefitinib)和厄洛替尼(erlotinib)双重耐药非小细胞肺癌(NSCLC)细胞HCC827/ER研究消癌平注射液(XAP)改善gefitinib和erlotinib耐药的作用及机理。方法：

会议

消癌平注射液非小细胞肺癌细胞耐药非小细胞肺癌检测细胞实时荧光定量蛋白表达水平耐药细胞株基因拷贝数

Field-controlled Magneto-electric Nanoparticles to Enable a Novel Mechanism for High-specificity Tar

　　Objective: This in vivo study on nude mice bearing SKOV-3 human ovarian carcinoma xenografts aims to show that intravenously administrated 30-nm CoFe2O4@BaT

会议

替莫唑胺联合依维莫司治疗复治的不可切除的Ⅲc期或Ⅳ期黑色素瘤患者的疗效及安全性分析

　　目的：哺乳动物雷帕霉素靶蛋白(mTOR)通路在恶性黑色素瘤中被激活.PI3K-Akt-mTOR信号通路的抑制与黑色素瘤对烷化剂(替莫唑胺)的敏感性密切相关，亦与肿瘤血管生成的抑制相关

会议

替莫唑胺依维莫司治疗复治不可切除恶性黑色素瘤患者疗效

肌层浸润性尿路上皮癌PD-L1表达及其临床意义

　　目的：晚期尿路上皮癌尚无标准二线治疗，近年来程序性死亡蛋白-配体1(PD-L1)单抗用于晚期尿路上皮癌的治疗初期临床研究有效，其效果与肿瘤PD-L1的表达密切相关。但国内关于尿

会议

浸润性尿路上皮癌PD-L1表达程序性死亡二线治疗临床意义临床研究

Efficacy of High-dose Adjuvant Interferon Therapy in High-risk Melanoma Harboring Gene Mutations

　　目的： BRAF/NRAS mutations are predictors of poor prognosis in melanoma.High-dose interferon (HDI) is the only drug approved by FDA as adjuvant therapy in hig

会议

adjuvant therapypoor prognosishighonlyBRAFHDIFDAare

A phase Ⅱ study of Everolimus for advanced melanoma patients with mTOR mutations

　　目的： Everolimus, an oral mTOR inhibitor, has shown minimal activity as a single agent in patients with metastatic melanoma unselected for potential predicti

会议

mTORagent

Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis

　　Objective: NIVO is a programmed death-1 (PD-1) immune checkpoint inhibitor which has shown durable tumor responses in multiple cancer types and prolongs ove

会议

Clinical response, progression-free survival(PFS), and safety in patients (pts) with advanced melano

　　Objective: Combined blockade of T-cell checkpoints by NIVO and IPI demonstrated a high objective response rate (ORR), promising overall survival (OS) and a

会议

Characteristic analysis of retinopathy associated with high doses of interferon α-2b therapy in pati

与本文相关的学术论文